Macrocyclic compounds and uses thereof
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF 1 R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
1. A method of treating a solid cancer in a patient in need thereof, comprising administering a therapeutically effective amount of a compound:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , comprising administering the compound having the structure:
3. The method of claim 1 , wherein the solid cancer is a metastatic cancer.
4. The method of claim 1 , wherein the solid cancer is oral cancer, thyroid cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, ovarian cancer, cervical cancer, uterine cancer, breast cancer, testicular cancer, prostate cancer, renal cancer, rectal cancer, kidney cancer, liver cancer, glioblastoma, head & neck cancer, or lung cancer.
5. The method of claim 1 , wherein the solid cancer is a lung cancer.
6. The method of claim 5 , wherein the lung cancer is non-small cell lung cancer.
7. A method of treating a cancer having Met amplification in a patient in need thereof, comprising administering a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , comprising administering the compound having the structure:
9. The method of claim 7 , wherein the cancer is a solid cancer.
10. The method of claim 9 , wherein the solid cancer is a metastatic cancer.
11. The method of claim 9 , wherein the solid cancer is oral cancer, thyroid cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, ovarian cancer, cervical cancer, uterine cancer, breast cancer, testicular cancer, prostate cancer, renal cancer, rectal cancer, kidney cancer, liver cancer, glioblastoma, head & neck cancer, or lung cancer.
12. The method of claim 9 , wherein the solid cancer is a lung cancer.
13. The method of claim 12 , wherein the lung cancer is non-small cell lung cancer.
14. A method of treating a cancer having a Met exon 14 mutation in a patient in need thereof, comprising administering a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.
15. The method of claim 14 , comprising administering the compound having the structure:
16. The method of claim 15 , wherein the cancer is a solid cancer.
17. The method of claim 16 , wherein the solid cancer is a metastatic cancer.
18. The method of claim 16 , wherein the solid cancer is oral cancer, thyroid cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, ovarian cancer, cervical cancer, uterine cancer, breast cancer, testicular cancer, prostate cancer, renal cancer, rectal cancer, kidney cancer, liver cancer, glioblastoma, head & neck cancer, or lung cancer.
19. The method of claim 16 , wherein the solid cancer is a lung cancer.
20. The method of claim 19 , wherein the lung cancer is non-small cell lung cancer.